Abstract
Intermedin (IMD) or adrenomedullin 2 is a novel peptide related to the calcitonin gene-related peptide (CGRP) family. Via calcitonin receptor-like receptor/receptor activity modifying proteins, the common receptor complexes of CGRP, IMD exerts a wide range of biological effects, especially regulation of cardiovascular homeostasis. Proteolytic processing of a larger IMD precursor yields a series of biologically active C-terminal fragments, IMD1-53, IMD1-47 and IMD8-47. IMD and its receptors are present in the cardiovascular system, and IMD is present at low levels in plasma. In the cardiovascular system, IMD has multiple functions such as regulation of blood pressure and cardiac function, pro-angiogenesis, endothelial barrier function protection, anti-oxidative stress, and anti-endoplasmic reticulum stress. IMD participates widely in the pathogenesis of atherosclerosis, hypertension, pulmonary arterial hypertension and vascular calcification. It is a vascular regulatory factor of homeostasis and a vital endogenous protective factor against vascular diseases.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Roh J, Chang CL, Bhalla A, Klein C, Hsu SY. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes. J Biol Chem, 2004, 279: 7264–7274
Kobayashi Y, Liu YJ, Gonda T, Takei Y. Coronary vasodilatory response to a novel peptide, adrenomedullin 2. Clin Exp Pharmacol Physiol, 2004, 31(Suppl 2): S49–S50
Taylor MM, Samson WK. Stress hormone secretion is altered by central administration of intermedin/adrenomedullin-2. Brain Res, 2005, 1045: 199–205
Taylor MM, Bagley SL, Samson WK. Intermedin/Adrenomedullin-2 inhibits growth hormone release from cultured, primary anterior pituitary cells. Endocrinology, 2006, 147: 859–864
Takahashi K, Kikuchi K, Maruyama Y, Urabe T, Nakajima K, Sasano H, Imai Y, Murakami O, Totsune K. Immunocytochemical localization of adrenomedullin 2/intermedin-like immunoreactivity in human hypothalamus, heart and kidney. Peptides, 2006, 27: 1383–1389
Hashimoto H, Hyodo S, Kawasaki M, Shibata M, Saito T, Suzuki H, Otsubo H, Yokoyama T, Fujihara H, Higuchi T, Takei Y, Ueta Y. Adrenomedullin 2 (AM2)/intermedin is a more potent activator of hypothalamic oxytocin-secreting neurons than AM possibly through an unidentified receptor in rats. Peptides, 2007, 28: 1104–1112
Song JQ, Teng X, Cai Y, Tang CS, Qi YF. Activation of Akt/GSK-3beta signaling pathway is involved in intermedin(1–53) protection against myocardial apoptosis induced by ischemia/reperfusion. Apoptosis, 2009, 14: 1061–1069
Pearson LJ, Yandle TG, Nicholls MG, Evans JJ. Intermedin (adrenomedullin-2): a potential protective role in human aortic endothelial cells. Cell Physiol Biochem, 2009, 23: 97–108
Du QX, Yue W, Wang YY. Effect and mechanism of intermedin in acute rat cardiac ischemic injury. Fa Yi Xue Za Zhi, 2011, 27: 164–168
Pires AL, Pinho M, Alves BS, Pinho S, Sena C, Seica RM, Leite-Moreira AF. Reverse myocardial effects of intermedin in pressure-overloaded hearts: role of endothelial nitric oxide synthase activity. J Physiol, 2013, 591 (Pt 3): 677–687
Hirose T, Totsune K, Mori N, Mori T, Morimoto R, Metoki H, Asayama K, Kikuya M, Ohkubo T, Kohzuki M, Takahashi K, Imai Y. Expression of adrenomedullin 2/intermedin, a possible renoprotective peptide, is decreased in the kidneys of rats with hypertension or renal failure. Am J Physiol Renal Physiol, 2010, 299: F128–F134
Guo X, Schmitz JC, Kenney BC, Uchio EM, Kulkarni S, Cha CH. Intermedin is overexpressed in hepatocellular carcinoma and regulates cell proliferation and survival. Cancer Sci, 2012, 103: 1474–1480
Zhang W, Wang LJ, Xiao F, Wei Y, Ke W, Xin HB. Intermedin: a novel regulator for vascular remodeling and tumor vessel normalization by regulating vascular endothelial-cadherin and extracellular signal-regulated kinase. Arterioscler Thromb Vasc Biol, 2012, 32: 2721–2732
Du X, Cao Y, Xue P, Lin Z, Zeng Z, Xia Q. Protective effect of intermedin on myocardial cell in a rat model of severe acute pancreatitis. Cell Mol Biol Lett, 2011, 16: 462–476
Cai Y, Xu MJ, Teng X, Zhou YB, Chen L, Zhu Y, Wang X, Tang CS, Qi YF. Intermedin inhibits vascular calcification by increasing the level of matrix gamma-carboxyglutamic acid protein. Cardiovasc Res, 2010, 85: 864–873
Dai XY, Cai Y, Mao DD, Qi YF, Tang C, Xu Q, Zhu Y, Xu MJ, Wang X. Increased stability of phosphatase and tensin homolog by intermedin leading to scavenger receptor A inhibition of macrophages reduces atherosclerosis in apolipoprotein E-deficient mice. J Mol Cell Cardiol, 2012, 53: 509–520
Zeng Q, Yuan Y, Wang X, Wu HM, Fan L, Qi YF, Tang CS, Cai Y, Pan CS. Upregulated expression of intermedin and its receptor in the myocardium and aorta in spontaneously hypertensive rats. Peptides, 2009, 30: 391–399
Yang JH, Jia YX, Pan CS, Zhao J, Ouyang M, Yang J, Chang JK, Tang CS, Qi YF. Effects of intermedin(1–53) on cardiac function and ischemia/reperfusion injury in isolated rat hearts. Biochem Biophys Res Commun, 2005, 327: 713–719
Morimoto R, Satoh F, Murakami O, Totsune K, Suzuki T, Sasano H, Ito S, Takahashi K. Expression of adrenomedullin2/intermedin in human brain, heart, and kidney. Peptides, 2007, 28: 1095–1103
Conner AC, Hay DL, Howitt SG, Kilk K, Langel U, Wheatley M, Smith DM, Poyner DR. Interaction of calcitonin-gene-related peptide with its receptors. Biochem Soc Trans, 2002, 30: 451–455
Chen H, Wang X, Tong M, Wu D, Wu S, Chen J, Wang X, Wang X, Kang Y, Tang H, Tang C, Jiang W. Intermedin suppresses pressure overload cardiac hypertrophy through activation of autophagy. PLoS One, 2013, 8: e64757
Li P, Sun HJ, Han Y, Wang JJ, Zhang F, Tang CS, Zhou YB. Intermedin enhances sympathetic outflow via receptor-mediated cAMP/PKA signaling pathway in nucleus tractus solitarii of rats. Peptides, 2013, 47: 1–6
Aslam M, Pfeil U, Gunduz D, Rafiq A, Kummer W, Piper HM, Noll T. Intermedin (adrenomedullin2) stabilizes the endothelial barrier and antagonizes thrombin-induced barrier failure in endothelial cell monolayers. Br J Pharmacol, 2012, 165: 208–222
Yuan Y, Wang X, Zeng Q, Wu HM, Qi YF, Tang CS. Effects of continuous intermedin infusion on blood pressure and hemodynamic function in spontaneously hypertensive rats. J Geriatr Cardiol, 2012, 9: 17–27
Pires AL, Pinho M, Sena CM, Seica R, Leite-Moreira AF. Intermedin elicits a negative inotropic effect in rat papillary muscles mediated by endothelial-derived nitric oxide. Am J Physiol Heart Circ Physiol, 2012, 302: H1131–H1137
Grossini E, Molinari C, Mary DA, Uberti F, Caimmi PP, Vacca G. Intracoronary intermedin 1–47 augments cardiac perfusion and function in anesthetized pigs: role of calcitonin receptors and beta-adrenoreceptor-mediated nitric oxide release. J Appl Physiol (1985), 2009, 107: 1037–1050
Kandilci HB, Gumusel B, Lippton H. Intermedin/adrenomedullin-2 (IMD/AM2) relaxes rat main pulmonary arterial rings via cGMP-dependent pathway: role of nitric oxide and large conductance calcium-activated potassium channels (BK(Ca)). Peptides, 2008, 29: 1321–1328
Chang JR, Duan XH, Zhang BH, Teng X, Zhou YB, Liu Y, Yu YR, Zhu Y, Tang CS, Qi YF. Intermedin 1–53 attenuates vascular smooth muscle cell calcification by inhibiting endoplasmic reticulum stress via cyclic adenosine monophosphate/protein kinase A pathway. Exp Biol Med (Maywood), 2013, 238: 1136–1146
Mao SZ, Fan XF, Xue F, Chen R, Chen XY, Yuan GS, Hu LG, Liu SF, Gong YS. Intermedin modulates hypoxic pulmonary vascular remodeling by inhibiting pulmonary artery smooth muscle cell proliferation. Pulm Pharmacol Ther, 2014, 27: 1–9
Jolly L, March JE, Kemp PA, Bennett T, Gardiner SM. Mechanisms involved in the regional haemodynamic effects of intermedin (adrenomedullin 2) compared with adrenomedullin in conscious rats. Br J Pharmacol, 2009, 157: 1502–1513
Smith RJ, Gao L, Bledsoe G, Chao L, Chao J. Intermedin is a new angiogenic growth factor. Am J Physiol Heart Circ Physiol, 2009, 297: H1040–H1047
Yang JH, Pan CS, Jia YX, Zhang J, Zhao J, Pang YZ, Yang J, Tang CS, Qi YF. Intermedin1-53 activates L-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Biochem Biophys Res Commun, 2006, 341: 567–572
Abdelrahman AM, Pang CC. Vasodilator mechanism of intermedin/adrenomedullin-2 in anesthetized rats. Proc West Pharmacol Soc, 2007, 50: 43–46
Aslam M, Gunduz D, Schuler D, Li L, Sharifpanah F, Sedding D, Piper HM, Noll T. Intermedin induces loss of coronary microvascular endothelial barrier via derangement of actin cytoskeleton: role of RhoA and Rac1. Cardiovasc Res, 2011, 92: 276–286
Zhang X, Gu L, Chen X, Wang S, Deng X, Liu K, Lv Z, Yang R, He S, Peng Y, Huang D, Jiang W, Wu K. Intermedin ameliorates atherosclerosis in ApoE null mice by modifying lipid profiles. Peptides, 2012, 37: 189–193
Dai XY, Cai Y, Sun W, Ding Y, Wang W, Kong W, Tang C, Zhu Y, Xu MJ, Wang X. Intermedin inhibits macrophage foam-cell formation via tristetraprolin-mediated decay of CD36 mRNA. Cardiovasc Res, 2014, 101: 297–305
Hirose T, Totsune K, Nakashige Y, Metoki H, Kikuya M, Ohkubo T, Hara A, Satoh M, Inoue R, Asayama K, Kondo T, Kamide K, Katsuya T, Ogihara T, Izumi S, Rakugi H, Takahashi K, Imai Y. Influence of adrenomedullin 2/intermedin gene polymorphism on blood pressure, renal function and silent cerebrovascular lesions in Japanese: the Ohasama study. Hypertens Res, 2011, 34: 1327–1332
Taylor MM, Bagley SL, Samson WK. Intermedin/adrenomedullin-2 acts within central nervous system to elevate blood pressure and inhibit food and water intake. Am J Physiol Regul Integr Comp Physiol, 2005, 288: R919–R927
Zhou YB, Sun HJ, Chen D, Liu TY, Han Y, Wang JJ, Tang CS, Kang YM, Zhu GQ. Intermedin in paraventricular nucleus attenuates sympathetic activity and blood pressure via nitric oxide in hypertensive rats. Hypertension, 2014, 63: 330–337
Hagiwara M, Bledsoe G, Yang ZR, Smith RJ, Chao L, Chao J. Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress. Am J Physiol Renal Physiol, 2008, 295: F1735–F1743
Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation, 2007, 116: 85–97
Gong YS, Fan XF, Wu XM, Hu LG, Tang CS, Pang YZ, Qi YF. Changes of intermedin/adrenomedullin 2 and its receptors in the right ventricle of rats with chronic hypoxic pulmonary hypertension (in Chinese). Sheng Li Xue Bao, 2007, 59: 210–214
Fan XF, Huang P, Gong YS, Wu XM, Hu LG, Tian LX, Tang CS, Pang YZ. Changes of adrenomedullin 2/intermedin in the lung of rats with chronic hypoxic pulmonary hypertension (in Chinese). Zhongguo Ying Yong Sheng Li Xue Za Zhi, 2007, 23: 467–471
Wu DF, Tian LX, Fan XF, Wu XM, Hu LG, Zhang L, Huang P, Gong YS. Effect of hypoxia on the expressions of intermedin/adrenomedullin2 and its receptors in the lung of rats. J Chin Microcirc, 2007, 11: 94–97
Yang SY, Guo ZY, Feng ZE, Yan ZQ, Wang SL, Qi YS, He W, Tian ZX, Yin H, Zhang Y. Changes of pulmonary vasoactive factors and its relation with pulmonary arterial hypertension in patients with chronic cor pulmonale at high altitude area. Chin J Lung Dis (Electronic Edition), 2011, 4: 211–215
Pang LL, Qi JG, Gao Y, Jin HF, Du JB. Intermedin alleviates pulmonary vascular structural remodeling induced by high pulmonary blood flow in rats. Basic Clin Med, 2013, 33: 1045–1049
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at link.springer.com
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Ni, X., Zhang, J., Tang, C. et al. Intermedin/adrenomedullin2: an autocrine/paracrine factor in vascular homeostasis and disease. Sci. China Life Sci. 57, 781–789 (2014). https://doi.org/10.1007/s11427-014-4701-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-014-4701-7